ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company's cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing. In addition, the Company also has a portfolio of other potential therapeutic immunotherapies using a range of approaches to treat cancer. Its other product candidates are ICT-140 and ICT-121. ICT-107 is a dendritic cell (DC) vaccine for the treatment of newly diagnosed glioblastoma multiforme (GBM), a type of brain cancer. ICT-140 is a DC vaccine that targets over seven tumor-associated antigens expressed on ovarian cancer cells. It is developing ICT-121, a dendritic cell (DC)-based vaccine targeting CD133+ CSCs for the treatment of recurrent GBM and other solid tumor cancers, including ovarian, pancreatic and breast cancers.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: NASDAQ:IMUC
- CUSIP: N/A
- Web: imuc.com/
- Market Cap: $5.54 million
- Outstanding Shares: 15,841,000
- 52 Week Range: $0.25 - $4.80
Sales & Book Value:
- Trailing P/E Ratio:
- Foreward P/E Ratio: -0.55
- P/E Growth:
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: ($0.83) per share
- Price / Book: -0.42
- EBIDTA: ($26,280,000.00)
- Return on Assets: -189.02%
- Average Volume: 1.95 million shs.
- Short Ratio: 0.35
Frequently Asked Questions for ImmunoCellular Therapeutics Ltd (NASDAQ:IMUC)
What is ImmunoCellular Therapeutics Ltd's stock symbol?
ImmunoCellular Therapeutics Ltd trades on the NASDAQ under the ticker symbol "IMUC."
Who are some of ImmunoCellular Therapeutics Ltd's key competitors?
Some companies that are related to ImmunoCellular Therapeutics Ltd include Synairgen plc (SNG), Ampliphi Biosciences Corp (APHB), Ixico Plc (IXI), Akers Biosciences (AKR), OncoGenex Pharmaceuticals (ACHV), Roka Bioscience (ROKA), Rosetta Genomics (ROSG), Anacor Pharmaceuticals (ANAC), ANI Pharmaceuticals (BPAX), Celator Pharmaceuticals (CPXX), Cellular Dynamics International (ICEL), Covance (CVD), Cyprotex plc (CRX), GenVec (GNVC), Mesoblast limited (MBLTY), Pharmacyclics (PCYC), Prosensa Holding NV (RNA) and Synageva Biopharma Corp (GEVA).
Who are ImmunoCellular Therapeutics Ltd's key executives?
ImmunoCellular Therapeutics Ltd's management team includes the folowing people:
- Anthony J. Gringeri Ph.D., President, Chief Executive Officer, Director
- David E. Fractor, Chief Financial Officer
- Rahul Singhvi, Lead Independent Director
- John S. Yu M.D., Director
- Anthony Gregg Lapointe, Independent Director
- Mark A. Schlossberg Esq., Independent Director
- Gary S. Titus, Independent Director
Who owns ImmunoCellular Therapeutics Ltd stock?
How do I buy ImmunoCellular Therapeutics Ltd stock?
Shares of ImmunoCellular Therapeutics Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ImmunoCellular Therapeutics Ltd's stock price today?
MarketBeat Community Rating for ImmunoCellular Therapeutics Ltd (NASDAQ IMUC)MarketBeat's community ratings are surveys of what our community members think about ImmunoCellular Therapeutics Ltd and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of ImmunoCellular Therapeutics Ltd stock can currently be purchased for approximately $0.35.
Consensus Ratings for ImmunoCellular Therapeutics Ltd (NASDAQ:IMUC) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Hold Rating|
|Consensus Rating:||Hold (Score: 2.00)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for ImmunoCellular Therapeutics Ltd (NASDAQ:IMUC)
(Data available from 9/23/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|8/24/2017||Maxim Group||Reiterated Rating||Hold||Medium|
Earnings History for ImmunoCellular Therapeutics Ltd (NASDAQ:IMUC)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for ImmunoCellular Therapeutics Ltd (NASDAQ:IMUC)
Current Year EPS Consensus Estimate: $-3.83 EPS
Next Year EPS Consensus Estimate: $-0.64 EPS
Dividend History for ImmunoCellular Therapeutics Ltd (NASDAQ:IMUC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for ImmunoCellular Therapeutics Ltd (NASDAQ:IMUC)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for ImmunoCellular Therapeutics Ltd (NASDAQ:IMUC)
Latest Headlines for ImmunoCellular Therapeutics Ltd (NASDAQ:IMUC)
ImmunoCellular Therapeutics Ltd (IMUC) Chart for Saturday, September, 23, 2017